<DOC>
	<DOCNO>NCT02578901</DOCNO>
	<brief_summary>The purpose study evaluate usefulness antifibrinolytic therapy tranexamic acid ( TXA ) prevent bleed patient thrombocytopenic due primary bone marrow disorder chemotherapy , immunotherapy and/or radiation therapy .</brief_summary>
	<brief_title>American Trial Using Tranexamic Acid Thrombocytopenia</brief_title>
	<detailed_description>The purpose study conduct prospective , randomize , blind , placebo control trial evaluate usefulness antifibrinolytic therapy tranexamic acid prevent bleed patient thrombocytopenic due primary bone marrow disorder chemotherapy , immunotherapy and/or radiation therapy . The result study change practice provide evidence whether TXA effective safe treatment use adjunct platelet transfusion therapy thrombocytopenic patient .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Inclusion criterion ( must meet ) : Must ≥ 18 year age Confirmed diagnosis hematologic malignancy aplasia Undergoing plan chemotherapy , immunotherapy , hematopoietic stem cell transplantation Anticipated hypoproliferative thrombocytopenia result platelet count ≤ 10,000/microliters ≥ 5 day Able provide inform consent comply treatment monitoring , Legally Authorized Representative ( LAR ) Exclusion criterion ( none present ) : Diagnosis acute promyelocytic leukemia undergo induction chemotherapy History ITP , TTP HUS Subjects receive Lasparaginase part current cycle treatment Subjects past history current diagnosis arterial venous thromboembolic disease include acute coronary syndrome , peripheral vascular disease retinal arterial venous thrombosis ( except prior history central line thrombosis resolve ) Subjects diagnosis/previous history sinusoidal obstruction syndrome ( also call venoocclusive disease ) Subjects receive procoagulant agent ( e.g . DDAVP , recombinant Factor VIIa Prothrombin Complex Concentrates ( PCC ) and/or antifibrinolytic agent within 48 hour enrollment , know hypercoagulable state Known inherit acquire bleed disorder include , limited : Acquired storage pool deficiency Paraproteinemia platelet inhibition Known inherit acquire prothrombotic disorder , include antiphospholipid syndrome . Those lupus anticoagulant positive antiphospholipid serology without thrombosis exclude . Subjects receive anticoagulant therapy antiplatelet therapy ( except receive prophylactic anticoagulant low dose aspirin therapy prophylaxis plan discontinue platelet count fall 50,000 ) Patients DIC accord patient 's physician Subjects WHO Grade 2 bleeding great within 48 hour prior activation Subjects require platelet transfusion threshold &gt; 10,000/microliters time randomization Subjects anuria ( defined urine output &lt; 10mls/hr 24 hour ) Subjects dialysis Subjects creatinine ≥5.7mg/dL Subjects pregnant nursing unwilling use contraception 30 day take study drug ( male female ) Subjects enrolled trial involve platelet transfusion , antifibrinolytics , platelet growth factor procoagulant agent . Known allergy tranexamic acid Having previously randomize study stage treatment Subjects unwilling accept blood blood component transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Tranexamic Acid</keyword>
	<keyword>TXA</keyword>
	<keyword>Chemotherapy induce thrombocytopenia</keyword>
</DOC>